Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Amgen
Pfizer
Pfizer
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Cancer Research UK
National Cancer Institute (NCI)
Cancer Research UK
Ikena Oncology
National Cancer Institute (NCI)
Aminex Therapeutics, Inc.
Novartis
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
University College, London
GE Healthcare
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center